知识与财富的链接
目的：研究雷公藤多甙（TII)治疗哮喘的机制,方法：选择中,重度哮发作期患者30例,随机分成3组。A组：T即Ⅱ治疗组,B组,泼尼松龙治疗组,C组,哮喘对照组,治疗前和治疗4周后分别用流式细胞仪（FCM）测定外周血CD^+4,CD^+8 T淋巴细胞数,用酶联免疫吸附法（ELISA）测血清白细胞介素－5（IL－5）的浓度,。结果：A组CD+4T 淋巴细胞由治疗前的0．462±0．035降至0．436±0．039（P＜0．01）,CD8 T10．9ng/L(P<0.01)。B组各指标治疗后变化与A组相似,而C组各指标治疗后均无明显改变,患者血清细胞亚群的紊乱,抑制IL－5的生成而对哮喘炎症产生治疗作用。
OBJECTIVE: To investigate the therapeutic mechanism of Tripterygium polyglucoside (TII) in treating asthma patients. METHODS: Thirty asthma patients of middle or sever leoel were selected and randomly divided into three groups, Group A treated with TII, Group B treated with prednisone and Group C, the control group. Their peripheral CD4+, CD8+ T-lymphocytes were counted by flow cytometer and serum interleukin-5 (IL-5) level determined by ELISA before and after 4 weeks' treatment. RESULTS: In Group A, after treatment, CD4+ T-lymphocytes reduced from 0.462 +/- 0.035 to 0.426 +/- 0.039 (P < 0.01), CD8+ increased from 0.201 +/- 0.045 to 0.253 +/- 0.043 (P < 0.01), and serum IL-5 median concentration reduced from 65.3 ng/L to 10.9 ng/L (P < 0.01). Similar results was revealed in Group B, while there was insignificant change of the parameters in Group C. The serum concentration of IL-5 was positively correlated with the peripheral CD4+ count (r = 0.61, P < 0.01). CONCLUSION: TII is highly effective in treating asthma through regulating T-lymphocyte subset disorder and inhibiting production of IL-5.
